<DOC>
	<DOC>NCT00920101</DOC>
	<brief_summary>The purpose of this study is to determine whether HMG-CoA reductase inhibitor, atorvastatin attenuates inflammation in atherosclerotic plaques detected by 18F-fluorodeoxyglucose(FDG) PET.</brief_summary>
	<brief_title>Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Plaque, Atherosclerotic</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Subjects with accumulation of FDGPET in carotid artery or aorta LDL cholesterol level (calculated by using Friedewald formula) higher than 180 mg/dl or less than 120 mg/dl subjects currently taking HMG CoAreductase (Statins) or fibrates symptomatic coronary artery diseases symptomatic cerebrovascular diseases subjects suffered from myocardial infarction or stroke within 6 months subjects underwent percutaneous vascular interventions or vascular operations within 6 months diabetic patients with poor glycemic control (HbA1c&gt;8.5) hypertensive patients with poor blood pressure control subjects with neoplasms subjects with systemic inflammatory diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>atherosclerotic plaques</keyword>
	<keyword>hypercholesterolemia</keyword>
	<keyword>HMG-CoA reductase inhibitor</keyword>
	<keyword>statin</keyword>
	<keyword>lipid-lowering therapy</keyword>
</DOC>